Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:KTTA NASDAQ:RVPH NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.46$0.63$0.30▼$3.42$18.76M-1.9350,348 shs1,330 shsKTTAPasithea Therapeutics$0.70$0.76$0.28▼$2.06$17.45M0.22311,882 shs334,625 shsRVPHReviva Pharmaceuticals$0.41$0.91$0.26▼$23.20$5.41M0.75582,872 shs82,201 shsTRAWTraws Pharma$1.49$1.67$1.00▼$3.27$15.14M1.476.37 million shs787,532 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%0.00%-4.17%+5.82%-58.93%KTTAPasithea Therapeutics0.00%-10.29%+1.42%-15.28%-23.54%RVPHReviva Pharmaceuticals0.00%+24.21%-54.13%-91.40%-98.00%TRAWTraws Pharma0.00%-20.74%+28.45%+4.20%+13.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.46$0.63$0.30▼$3.42$18.76M-1.9350,348 shs1,330 shsKTTAPasithea Therapeutics$0.70$0.76$0.28▼$2.06$17.45M0.22311,882 shs334,625 shsRVPHReviva Pharmaceuticals$0.41$0.91$0.26▼$23.20$5.41M0.75582,872 shs82,201 shsTRAWTraws Pharma$1.49$1.67$1.00▼$3.27$15.14M1.476.37 million shs787,532 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%0.00%-4.17%+5.82%-58.93%KTTAPasithea Therapeutics0.00%-10.29%+1.42%-15.28%-23.54%RVPHReviva Pharmaceuticals0.00%+24.21%-54.13%-91.40%-98.00%TRAWTraws Pharma0.00%-20.74%+28.45%+4.20%+13.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AKTTAPasithea Therapeutics 1.67Reduce$3.00328.69% UpsideRVPHReviva Pharmaceuticals 2.50Moderate Buy$66.6716,042.05% UpsideTRAWTraws Pharma 2.50Moderate Buy$8.00436.91% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, KTTA, TRAW, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/1/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)4/21/2026RVPHReviva Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/8/2026RVPHReviva Pharmaceuticals Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/5/2026RVPHReviva Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.20 per shareN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/A$1.48 per shareN/ATRAWTraws Pharma$2.79M5.43$0.76 per share1.95($0.52) per share-2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%5/25/2026 (Estimated)KTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%6/3/2026 (Estimated)RVPHReviva Pharmaceuticals-$19.86M-$4.06N/AN/AN/AN/A-391.58%-119.08%8/13/2026 (Estimated)TRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)Latest RVPH, KTTA, TRAW, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AKTTAPasithea Therapeutics-$3.40N/AN/AN/A$0.30 millionN/A5/25/2026Q3 2026ANEBAnebulo Pharmaceuticals-$0.14N/AN/AN/AN/AN/A5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/14/2026Q1 2026RVPHReviva Pharmaceuticals-$0.3550-$0.46-$0.1050-$0.46N/AN/A4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24KTTAPasithea TherapeuticsN/A35.4111.35RVPHReviva PharmaceuticalsN/A2.082.08TRAWTraws PharmaN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%KTTAPasithea Therapeutics23.92%RVPHReviva Pharmaceuticals63.18%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%KTTAPasithea Therapeutics2.00%RVPHReviva Pharmaceuticals8.90%TRAWTraws Pharma14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableRVPHReviva Pharmaceuticals513.11 million11.67 millionOptionableTRAWTraws Pharma1710.16 million8.74 millionNo DataRVPH, KTTA, TRAW, and ANEB HeadlinesRecent News About These CompaniesTraws Pharma (NASDAQ:TRAW) Receives Buy Rating from HC WainwrightMay 21, 2026 | americanbankingnews.comBioVie (NASDAQ:BIVI) vs. Traws Pharma (NASDAQ:TRAW) Financial ComparisonMay 20, 2026 | americanbankingnews.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNewtown-based Traws Pharma shares full-year results, clinical progressApril 23, 2026 | msn.comTraws Pharma Takes Flight: Revolutionary Flu Prophylactic Poised to SoarApril 21, 2026 | news.themarketisopen.comNTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?April 20, 2026 | zacks.comTraws Pharma, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comTraws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...April 16, 2026 | finance.yahoo.comTraws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027April 16, 2026 | seekingalpha.comTraws Pharma Announces Up to $60 Million Private Placement FinancingApril 16, 2026 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Q4 2025 Earnings Call TranscriptApril 16, 2026 | seekingalpha.comTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsApril 15, 2026 | globenewswire.comTraws Pharma Secures $10 Million PIPE Financing to Advance Influenza Program in Human Challenge TrialApril 15, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVPH, KTTA, TRAW, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.46 0.00 (0.00%) As of 05/22/2026 03:35 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Pasithea Therapeutics NASDAQ:KTTA$0.70 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.73 +0.03 (+3.74%) As of 05/22/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Reviva Pharmaceuticals NASDAQ:RVPH$0.41 0.00 (0.00%) As of 05/22/2026 03:50 PM EasternReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Traws Pharma NASDAQ:TRAW$1.49 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.60%) As of 05/22/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
